James Daniel Guylain Priour Net Worth

The estimated Net Worth of James Priour is at least $35.7 Thousand dollars as of 13 April 2021. Mr Priour owns over 2,266 units of Zymeworks BC Inc stock worth over $35,731 and over the last 4 years he sold ZYME stock worth over $0.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

or

Sign up with Google Sign up with Facebook

Mr Priour ZYME stock SEC Form 4 insiders trading

Mr has made over 1 trades of the Zymeworks BC Inc stock since 2021, according to the Form 4 filled with the SEC. Most recently he exercised 2,266 units of ZYME stock worth $27,419 on 13 April 2021.

The largest trade he's ever made was exercising 2,266 units of Zymeworks BC Inc stock on 13 April 2021 worth over $27,419. On average, Mr trades about 755 units every 0 days since 2021. As of 13 April 2021 he still owns at least 2,953 units of Zymeworks BC Inc stock.

You can see the complete history of Mr Priour stock trades at the bottom of the page.

Mr. James Daniel Guylain Priour biography

James Daniel Guylain Priour is the Chief Commercial Officer at Zymeworks BC Inc.

How old is Mr Priour?

Mr Priour is 54, he's been the Chief Commercial Officer of Zymeworks BC Inc since . There are 4 older and 2 younger executives at Zymeworks BC Inc. The oldest executive at Zymeworks BC Inc is Dr. Jennifer Kaufman-Shaw L.L.B., LLB, Ph.D., 71, who is the VP of Intellectual Property.

What's Mr Priour's mailing address?

James's mailing address filed with the SEC is C/O ZYMEWORKS INC., 1385 WEST 8TH AVENUE, SUITE 540, VANCOUVER, A1, V6H 3V9.

Insiders trading at Zymeworks BC Inc

Over the last 6 years, insiders at Zymeworks BC Inc have traded over $15,586,802 worth of Zymeworks BC Inc stock and bought 5,881,975 units worth $49,789,204 . The most active insiders traders include Bros. Advisors Lp667, L.P.B..., Capital, Llc Eco R1, and Group, Llc Green Jeremy Red.... On average, Zymeworks BC Inc executives and independent directors trade stock every 37 days with the average trade being worth of $1,629,555. The most recent stock trade was executed by Kenneth Galbraith on 5 January 2024, trading 47,666 units of ZYME stock currently worth $576,759.

What does Zymeworks BC Inc do?

zymeworks is a privately held biotherapeutics company that is developing best-in-class azymetric™ bi specific antibodies and antibody drug conjugates for the treatment of oncology, autoimmunity and inflammatory diseases. the company’s novel azymetric™ and albucore™ platforms, and its proprietary zymecad™ structure-guided protein engineering technology, enable the development of highly potent bi-specific antibodies and multivalent protein therapeutics targeted across a range of indications. zymeworks is focused on accelerating its preclinical biotherapeutics pipeline through in-house research and development programs and strategic collaborations. more information on zymeworks can be found at www.zymeworks.com.

Complete history of Mr Priour stock trades at Zymeworks BC Inc

Zymeworks BC Inc executives and stock owners

Zymeworks BC Inc executives and other stock owners filed with the SEC include:

• Dr. Ali Tehrani,
  Co-Founder, Pres, CEO & Director
• Dr. Anthony J. Polverino Ph.D.,
  Chief Scientific Officer & Exec. VP of Early Devel.
• Neil A. Klompas C.A., CPA, CPA, CA,
  Exec. VP of Bus. Operations & CFO
• Kathryn O'Driscoll,
  Chief People Officer
• Wajida Leclerc,
  VP of HR
• Dr. Jennifer Kaufman-Shaw L.L.B., LLB, Ph.D.,
  VP of Intellectual Property
• Dr. David Poon Ph.D.,
  VP of Bus. Devel. and Alliance Management
• James Daniel Guylain Priour,
  Chief Commercial Officer
• Dr. Neil Josephson M.D.,
  Chief Medical Officer
• Daniel Dex,
  VP of Legal & Corp. Sec.
• Neil Gallagher,
  
• Jeffrey T L Smith,
  EVP & Chief Medical Officer
• Kenneth Galbraith,
  Chair & CEO
• James Priour,
  Chief Commercial Officer
• Carlos Campoy,
  
• Lilly & Co Eli,
  10% owner
• Alessandra Cesano,
  
• Ali Tehrani,
  Chief Executive Officer
• David Kai Yuen Poon,
  See Remarks
• Diana Hausman,
  Chief Medical Officer
• Anthony J. Polverino,
  Chief Scientific Officer
• Nick Bedford,
  Director
• Natalie Sacks,
  Director
• Kenneth J. Hillan,
  
• Lota S. Zoth,
  Director
• Leone D Patterson,
  EVP, Chief Bus & Fin Officer
• Capital, Llc Eco R1,
  10% owner
• Bros. Advisors Lp667, L.P.B...,
  
• Paul Andrew Moore,
  Chief Scientific Officer
• Christopher Astle,
  SVP & Chief Financial Officer
• Neil A Klompas,
  President & COO
• Neil Josephson,
  Chief Medical Officer
• Group, Llc Green Jeremy Red...,
  
• Nancy Davidson,
  
• Susan Mahony,
  
• Hollings Renton,
  
• Derek John Michael Miller,
  
• Troy Cox,
  
• Kelvin Neu,